MedPath

Radiotherapy Planning Based on Positron Emission Tomography With Fluoro-deoxyglucose For Advanced NSCLC

Phase 2
Conditions
Non-small Cell Lung Cancer
Interventions
Procedure: restriction of radiotherapy to FDG-PET positive areas only
Registration Number
NCT00697333
Lead Sponsor
Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN
Brief Summary

Simultaneous radio-chemotherapy in advanced non-small cell lung cancer. The study focusses on a randomised comparison of conventional radiotherapy planning with irradiation of macroscopic tumor and lymph nodes together with prophylactic target volumes vs. irradiation only of FDG-positive lesions.

Primary endpoint is the local disease control in the chest.

Detailed Description

Simultaneous radio-chemotherapy in advanced non-small cell lung cancer. The study focusses on a randomised comparison of conventional radiotherapy planning with irradiation of macroscopic tumor and lymph nodes together with prophylactic target volumes vs. irradiation only of FDG-positive lesions.

Primary endpoint is the local disease control in the chest

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  • histologically proved NSCLC
  • UICC-stage I-III, no resection planned
  • complete staging < 6 wks before treatment including cranial CT
  • ECOG <3, Karnofsky-Index >60%
  • age > 18 <
  • FEV1 > 1,0 l or >35%
  • RT-planning according to protocol feasible
  • chemotherapy feasible
  • written informed consent
Exclusion Criteria
  • neuroendocrine tumors, plain broncho-alveolar-cell ca.
  • distant metastases, supraclavicular lymph node metastases
  • malignant pleural effusion
  • resection of actual tumor performed
  • inclusion in other study protocol
  • chemotherapy due to actual tumor before FDG-PET
  • induction-chemotherapy
  • acute vena cava superior syndrome
  • second malignancy other than basalioma
  • pregnancy, lactation
  • heart insufficiency NYHA III/IV
  • pneumoconiosis with active inflammatory changes of mediastinal lymph nodes
  • acute broncho-pulmonary infection at time of PET-examination

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Brestriction of radiotherapy to FDG-PET positive areas onlyIrradiation of all tumor manifestations detectable by positron emission tomography using fluoro-deoxy-glucose including the whole affected lymph node stations by 60 - 74 Gy/2Gy
Primary Outcome Measures
NameTimeMethod
time to local progressionactuarial

Time from randomization to first evidence of local progression or last follow up

Secondary Outcome Measures
NameTimeMethod
Overall survivalactuarial

Time from randomization to death or last follow up

normal tissue toxicityactuarial

Time from randomization to death or last follow up

in and out field progressionactuarial

Time from randomization to progression or last follow up

Trial Locations

Locations (1)

Universitätsklinikum Freiburg

🇩🇪

Freiburg i. Br., Baden-Württemberg, Germany

© Copyright 2025. All Rights Reserved by MedPath